Search

Your search keyword '"Barbaud A"' showing total 8,443 results
Start Over "Barbaud A"

Refine your results

more »

more »

more »

more »

more »

more »

more »

more »
8,443 results on '"Barbaud A"'

51. Linear Immunoglobulin a Bullous Dermatosis in Children

Author

Francesca Mori, Francesca Saretta, Lucia Liotti, Mattia Giovannini, Riccardo Castagnoli, Stefania Arasi, Simona Barni, Carla Mastrorilli, Luca Pecoraro, Lucia Caminiti, Gian Luigi Marseglia, Annick Barbaud, and Elio Novembre

Subjects
linear IgA bullous dermatosis (LABD), newborn, children, drug hypersensitivity, epidemiology, diagnosis, Pediatrics, RJ1-570
Abstract

Linear Immunoglobulin A Bullous Disease (LABD) is a rare dermatosis whose pathomechanisms are not yet completely understood. LABD has different features characterizing adults and children in terms of potential triggers, clinical manifestations, and prognosis. The aim of the present study is to review all neonatal and pediatric cases of LABD and summarize the major characteristics. Childhood LABD is mainly idiopathic with a benign prognosis. Neonatal cases are difficult to differentiate from infectious diseases and usually have a poor prognosis. Drugs are one of the possible triggers that can activate autoimmune responses through antigen mimicry and epitope spreading as well as different stimuli (e.g., infections, inflammatory diseases, trauma). The gold standard for the diagnosis is based on direct immunofluorescence. Prognosis is generally favorable but often depends on the prompt dermatological diagnosis, treatment and follow-up guaranteed by a multidisciplinary team, including pediatricians for this group of age.

Published
2022
Full Text
View/download PDF

52. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.

Author

Brüggen, Marie-Charlotte, Walsh, Sarah, Ameri, M. Milad, Anasiewicz, Natalie, Maverakis, Emanual, French, Lars E., Ingen-Housz-Oro, Saskia, Abe, Richiiro, Ardern-Jones, Michael, Assier, Haudrey, Barbaud, Annick, Bensaid, Benoit, Bernal, William, Bernier, Claire, Brassard, Alain, Březinová, Eva, Cabañas, Rosario, Cardones, Adela, Chu, Chia-Yu, and Chua, Ser-Ling

Published
2024
Full Text
View/download PDF

54. La place Amédée-Larrieu, un rare ensemble Art Nouveau signé Edouard Bauhain, Raymond Barbaud et Raoul Verlet

Author

Delorme, Franck, Delorme, Franck, Société archéologique de Bordeaux, Identités, Territoires, Expressions, Mobilités (ITEM), and Université de Pau et des Pays de l'Adour (UPPA)

Subjects
Histoire de l'art, Urbanisme, [SHS.ARCHI]Humanities and Social Sciences/Architecture, space management, Architecture, Histoire contemporaine, [SHS.ART] Humanities and Social Sciences/Art and art history, [SHS.ART]Humanities and Social Sciences/Art and art history, [SHS.ARCHI] Humanities and Social Sciences/Architecture, space management, Bordeaux, Esthétique, ComputingMilieux_MISCELLANEOUS, [SHS]Humanities and Social Sciences
Abstract

International audience; La forte tradition architecturale classique de Bordeaux n'a pas empêché, par moment, les mariages réussis avec d'autres sources d'inspiration. La place Amédée-Larrieu, avec sa fontaine et son ancien marché couvert, est une tentative intéressante en matière d'évolution esthétique et stylistique. En signant, en 1901, cet ensemble unique et remarquable, les architectes Edouard Bauhain et Raymond Barbaud, associés au sculpteur Raoul Verlet, ont su puiser dans le répertoire classique tout en y introduisant les accents fluides et souples de l'Art nouveau alors en pleine vogue. La fontaine s'inscrit dans l'histoire de fontaines publiques bordelaises par son réel statut de monument autant que d'oeuvre d'art. Le groupe sculpté qui la compose est très représentatif de la production de Raoul Verlet que de la pratique de la sculpture autour de 1900 Le marché couvert est, par sa taille modeste mais sa grande qualité de dessin et de composition, un des équipements publics dont sont équipés les différents quartiers de Bordeaux dans la fin du XIXe siècle et le début du XXe siècle. Il témoigne aussi parfaitement de l'intérêt que représente le travail de ses deux architectes.

Published
2012

57. Risk stratification through extensive allergy work‐up in COVID‐19‐mRNA vaccine allergic reactions.

Author

Soria, Angèle, Labella, Marina, Doña, Inmaculada, Nicaise‐Roland, Pascale, Chollet‐Martin, Sylvie, Autegarden, Jean‐Eric, Castagna, Julie, Le Thai, Claire, de Chaisemartin, Luc, Torres, Maria José, and Barbaud, Annick

Subjects
ALLERGIES, VACCINES, ANAPHYLAXIS, SKIN tests, POLYETHYLENE glycol
Abstract

In 145 patients, revaccination was performed with the culprit vaccine, which was well tolerated in 126 of the patients, and 15 of the patients had an alternative COVID-19 vaccine (other mRNA vaccine for 12), which was well tolerated in 13 of the patients (Figure 1). Keywords: allergy; anaphylaxis; COVID-19-mRNA vaccines EN allergy anaphylaxis COVID-19-mRNA vaccines 2320 2323 4 08/02/23 20230801 NES 230801 To the Editor, The mechanisms of allergic reactions to COVID-19-mRNA vaccines have not been elucidated. One hundred and sixty patients (84%) were revaccinated (122 under antihistamine premedication), 139 patients (87%) had good tolerance, and 30 patients refused further COVID-19 vaccination. [Extracted from the article]

Published
2023
Full Text
View/download PDF

64. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.

Author

Mayorga C, Çelik GE, Pascal M, Hoffmann HJ, Eberlein B, Torres MJ, Brockow K, Garvey LH, Barbaud A, Madrigal-Burgaleta R, Caubet JC, and Ebo DG

Subjects
Humans, Child, Basophil Degranulation Test methods, Basophils, COVID-19 Vaccines, Hypersensitivity, Immediate, Drug Hypersensitivity diagnosis, Hypersensitivity
Abstract

Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) "Basophil activation test in the evaluation of Drug Hypersensitivity Reactions" from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

72. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper

Author

Bavbek, Sevim, primary, Kepil Özdemir, Seçil, additional, Bonadonna, Patrizia, additional, Atanaskovic‐Markovic, Marina, additional, Barbaud, Annick, additional, Brockow, Knut, additional, Laguna Martinez, Jose, additional, Nakonechna, Alla, additional, Pagani, Mauro, additional, Arcolacı, Alessandra, additional, Lombardo, Carla, additional, and Torres, Maria J., additional

Published
2023
Full Text
View/download PDF

74. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

Author

Maurer, Marcus, primary, Ensina, Luis Felipe, additional, Gimenez-Arnau, Ana Maria, additional, Sussman, Gordon, additional, Hide, Michihiro, additional, Saini, Sarbjit, additional, Grattan, Clive, additional, Fomina, Daria, additional, Rigopoulos, Dimitrios, additional, Berard, Frederic, additional, Canonica, Giorgio Walter, additional, Rockmann, Heike, additional, Irani, Carla, additional, Szepietowski, Jacek C, additional, Leflein, Jeffrey, additional, Bernstein, Jonathan A, additional, Peter, Jonny G, additional, Kulthanan, Kanokvalai, additional, Godse, Kiran, additional, Ardusso, Ledit, additional, Ukhanova, Olga, additional, Staubach, Petra, additional, Sinclair, Rodney, additional, Gogate, Shaila, additional, Thomsen, Simon Francis, additional, Tanus, Tonny, additional, Ye, Young Min, additional, Burciu, Alis, additional, Barve, Avantika, additional, Modi, Darshna, additional, Scosyrev, Emil, additional, Hua, Eva, additional, Letzelter, Kerstin, additional, Varanasi, Vineeth, additional, Patekar, Manmath, additional, Severin, Thomas, additional, Rosana, Agondi, additional, Ahmed, Al Waily, additional, Fabio, Almerigogna, additional, Miguel Angel Tejedor, Alonso, additional, Alfred, Ammoury, additional, Eng Kim, Anne Goh, additional, Robert, Anolik, additional, Ledit, Ardusso, additional, Petr, Arenberger, additional, Nandini, AS, additional, Mohammad, Asefi, additional, Natalia, Astafieva, additional, Anil, Badhwar, additional, Esther Serra, Baldrich, additional, Christine, Bangert, additional, Annick, Barbaud, additional, Zsuzsanna, Bata-Csorgo, additional, Andrea, Bauer, additional, Frederic, Berard, additional, Beata, Bergler-Czop, additional, Gary D, Berman, additional, Jonathan, Bernstein, additional, Subhash Chandra, Bharija, additional, Ramesh M, Bhat, additional, Isabelle, Boccon-Gibod, additional, Ivan, Botev, additional, Knut, Brockow, additional, Philipp, Buck, additional, Paula, Busse, additional, Regis, Campos, additional, Giorgio Walter, Canonica, additional, Julia Maria Del, Carmen, additional, Jaime Del, Carpio, additional, Mamatha, Chadalavada, additional, Yoon-Seok, Chang, additional, Amarjit, Cheema, additional, Yi Hsing, Chen, additional, Yuko, Chinuki, additional, Soyun, Cho, additional, Jeong-Hee, Choi, additional, Chia-Yu, Chu, additional, Ronit, Confino, additional, Jonathan, Corren, additional, Roberta, Criado, additional, Claudia De La, Cruz, additional, David M, Cypcar, additional, Pramila, Daftary, additional, Inna, Danilycheva, additional, Kenneth, Dawes, additional, Michelle Joy, De Vera, additional, James, Deangelo, additional, Stefano, Del Giacco, additional, Diana, Deleanu, additional, John, Delgado, additional, Richard, DeMera, additional, Mohamed, Denguezli, additional, Heinrich, Dickel, additional, Le Huu, Doanh, additional, Sinan, Dogan, additional, Marie Sylvie, Doutre, additional, Anne Sophie, Dupond, additional, Anton, Edin, additional, Kent, EDWARD, additional, Swarna, Ekanayake-Bohling, additional, Daniel, Elbirt, additional, David, Elkayam, additional, Anne, Ellis, additional, Shaunagh, Emanuel, additional, Alexander, Emeliyanov, additional, Burhan, Engin, additional, Luis Felipe, Ensina, additional, Ignacio Antepara, Ercoreca, additional, Safiye, Ergun, additional, Jose Luis Lopez, Estebaranz, additional, Rustem, Fassakhov, additional, Daria, Fomina, additional, Linda, Ford, additional, Mariangela, Francomano, additional, Todd, Funkhouser, additional, Remi, Gagnon, additional, Ricardo, Galimberti, additional, Cesar Alberto, Galvan Calle, additional, Clovis, Galvao, additional, Gabriel, Gattolin, additional, Pierre-Dominique, Ghislain, additional, Ana Maria, Gimenez Arnau, additional, Elliot, Ginchansky, additional, Francoise, Giordano-Labadie, additional, Stanislav, Givirovsky, additional, Kiran, Godse, additional, Shaila, Gogate, additional, Alan, Goldsobel, additional, Francisca, Gomez, additional, Rene Maximiliano, Gomez, additional, Erika, Gonzalez, additional, Paula Ribo, Gonzalez, additional, Dimitar, Gospodinov, additional, Clive, Grattan, additional, Martine, Grosber, additional, Gary, Gross, additional, Francisco Jose Gomez, Guimera Martin-Neda, additional, Rolland, Gyulai, additional, Svetlana, Hadvabova, additional, Suzana Ljubojevic, Hadzavdic, additional, Hadi, Hamam, additional, Daniela, Hasicova, additional, Koremasa, Hayama, additional, Pravin, Hissaria, additional, Anna, Hjerppe, additional, Ivan, Hlinka, additional, Moises Labrador, Horrillo, additional, Connie, Hsu, additional, Yu-Huei, Huang, additional, Iftikhar, Hussain, additional, Atsuyuki, Igarashi, additional, Beata, IMKO-WALCZUK, additional, Huseyin Serhat, Inaloz, additional, Rossella, Intravaia, additional, Neal, Jain, additional, Sanjeev, Jain, additional, Thilo, Jakob, additional, Ruth Cerino, Javier, additional, Antonio, João, additional, Luiza Marek, Jozefowicz, additional, Chang-Gyu, Jung, additional, Martin, Kaatz, additional, Nida, Kacar, additional, Henry, Kanarek, additional, Iva, Karlova, additional, Alexander, Kastanayan, additional, Jana, Kazandjieva, additional, Johannes, Kern, additional, Aharon, Kessel, additional, Neena, Khanna, additional, HeeJoo, Kim, additional, Nancy, Kim, additional, Sang-Ha, Kim, additional, Tae-bum, Kim, additional, Kulli, Kingo, additional, Andreas, Kleinheinz, additional, Janka, Komova, additional, Evangelia, Kompoti, additional, Tomas, Kopal, additional, Peter, Kozub, additional, Dorota, Krasowska, additional, Beata, Krecisz, additional, Burkhard, Kreft, additional, Satsuki, Kubota, additional, Hitoshi, Kudo, additional, Teja, Kulkarni, additional, Kanokvalai, Kulthanan, additional, Akihiro, Kume, additional, Maciej, Kupczyk, additional, Edward, Lain, additional, Bobby, Lanier, additional, Hilde, Lapeere, additional, Griselle Ortiz, Lasanta, additional, Svetlana, Lazareva, additional, Laura, Lazzeri, additional, Dennis, Ledford, additional, Donghun, Lee, additional, Haur Yueh, Lee, additional, Jeffrey, Leflein, additional, Nicolas, Leitz, additional, Nancy, Levin, additional, Hermenio, Lima, additional, Undine, Lippert, additional, Brian, Lipson, additional, Paula, Luna, additional, Gabriel, Magarinos, additional, Satyaprakash, Mahajan, additional, Michail, Makris, additional, Alejandro, Malbran, additional, Ahmed Manjra, Manjra, additional, Michael, Manning, additional, Maria, Manrique, additional, Adriana, Marcipar, additional, Mariano, Marini, additional, Veronique Del, Marmol, additional, Jorge, Maspero, additional, Tomoko, Matsuda, additional, Jonathan, Matz, additional, Marcus, Maurer, additional, Wendy, McFalda, additional, Anne, Mclaughlin, additional, Iris, Medina, additional, Rajesh Dutt, Mehta, additional, Stephan, Meller, additional, Steven, MELTZER, additional, Raisa, Meshkova, additional, Dorin, Mihalache, additional, Francisco Javier, Miquel, additional, Mourad, Mokni, additional, J, Molhoek, additional, Efrain, Montano, additional, Sabine, Mueller, additional, Javier Pedraz, Munoz, additional, Toshikazu, Nagakura, additional, Joanna, Narbutt, additional, Ignasi Figueras, Nart, additional, Ma. Lourdes M, Nebrida-Idea, additional, Trong Hao, Nguyen, additional, Johannes, Niesmann, additional, Violeta Zaragoza, Ninet, additional, Hiromitsu, Noguchi, additional, Yuko Chinuki, Nomura, additional, Roman, Nowicki, additional, Tokuya, Omi, additional, Robert, Onder, additional, Ivan, Orojan, additional, Francisco Javier, Ortiz de Frutos, additional, Kim, Papp, additional, Claudio, Parisi, additional, Chun Wook, Park, additional, Heungwoo, Park, additional, Jungwon, Park, additional, Young Min, Park, additional, Viviana, Parra, additional, Thierry, Passeron, additional, Justine, Pasteur, additional, Shivakumar, Patil, additional, Vergil, Patrascu, additional, Sylvia, Pauser, additional, Anna Wojas, Pelc, additional, Jonathan Grant, Peter, additional, Wolfgang, Pfuetzner, additional, Nicola, Pimpinelli, additional, Andreas, Pinter, additional, Cristian, Pizarro, additional, Karel, Pizinger, additional, Jarmila, Plutinska, additional, Todor, Popov, additional, Veronika, Popova, additional, Marta Ferrer, Puga, additional, Lara Ferrandiz, Pulido, additional, Anca, Purcaru, additional, Ulrike, Raap, additional, Anna, Rajchel, additional, John, Ramey, additional, Ma Deanna Santos, Ramiscal, additional, German Dario, Ramon, additional, Syed, Rehman, additional, Adam, Reich, additional, Norbert, Reider, additional, Krista, Ress, additional, Dimitrios, Rigopoulos, additional, Enrique, Rivas, additional, Heike, Rockmann, additional, Pierre-Paul, Roquet-Gravy, additional, Menachem, Rottem, additional, Vermen Verallo, Rowell, additional, Franziska, Rueff, additional, Juan Alberto Ruano, Ruiz, additional, Juan, Russo, additional, Ronald, Saff, additional, Sarbjit, Saini, additional, Maria, Salazar, additional, Juan Francisco Silvestre, Salvador, additional, Jorge, Sanchez, additional, Florica, Sandru, additional, Mark, Scarupa, additional, Knut, Schaekel, additional, Sibylle, Schliemann, additional, Rik, Schrijvers, additional, Beate, Schwarz, additional, Andreas, Schwinn, additional, Sudhir, Sekhsaria, additional, Nilgun, Senturk, additional, Seong Jun, Seo, additional, Mercedes Rodriguez, Serna, additional, Faradiba, Serpa, additional, Paul A, Shapero, additional, Eriko, Shinkawa, additional, Jan-Christoph, Simon, additional, Rodney, Sinclair, additional, Ralfi, Singer, additional, Dareen D, Siri, additional, Karl, Sitz, additional, Adam, Smialowski, additional, Andrew, Smith, additional, Morten, Soerensen, additional, Wiebke, Sondermann, additional, Haejun, Song, additional, Dmitrii, Sonin, additional, Weily, Soong, additional, Daniel, Soteres, additional, Maria, Staevska-Kotasheva, additional, Petra, Staubach-Renz, additional, Nisha Su Yien, Subash, additional, Gordon, Sussman, additional, Ake Svensson, Svensson, additional, Ekaterini, Syrigou, additional, Andrea, Szegedi, additional, Jacek, Szepietowski, additional, Shunsuke, Takahagi, additional, Yuval, Tal, additional, Neetu, Talreja, additional, Wooi Chiang, Tan, additional, Ricardo, Tan, additional, Jyh Jong, Tang, additional, Tonny, Tanus, additional, Martha, Tarpay, additional, Shang Ian, Tee, additional, Craig, Teller, additional, Florence, Tetart, additional, Aurelie Du, Thanh, additional, Suganthi, Thevarajah, additional, Simon Francis, Thomsen, additional, Carl, Thornblade, additional, Milan, Tjioe, additional, Alberto, Tolcachier, additional, Celeste, Tolentino, additional, Athanasios, Tsianakas, additional, Ilia, Tsingov, additional, Hamida, Turki, additional, Olga, Ukhanova, additional, Jens, Ulrich, additional, Meltem, Uslu, additional, Fernando, Valenzuela, additional, Solange, Valle, additional, Martijn, van Doorn, additional, Jirina, Vankova, additional, Suneel, Vartak, additional, Christine, Vidouria, additional, Sebastian, Volc, additional, Gerald, Volcheck, additional, Nicola, Wagner, additional, Irena, Walecka-Herniczek, additional, Penpun, Wattanakrai, additional, Bettina, Wedi, additional, Steven, Weinstein, additional, Vesarat, Wessagowit, additional, Hugh, Windom, additional, Akiko, Yagami, additional, Aisaku, Yamamoto, additional, Shinichiro, Yasumoto, additional, Young Min, Ye, additional, Jose Cevallos, Yepez, additional, Sang Woong, Youn, additional, Hana, Zelenkova, additional, Oleg, Ziganshin, additional, and Matthew, Zook, additional

Published
2023
Full Text
View/download PDF

78. Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure

Author

Xiao Liu, Yanbo Wang, Tianhao Wu, Xin He, Xiangyue Meng, Julien Barbaud, Han Chen, Hiroshi Segawa, Xudong Yang, and Liyuan Han

Subjects
Science
Abstract

Tin based perovskite solar cells could be promising replacements for lead based counterparts due to their lower toxicity, but their efficiencies are much lower. Here, Liu et al. report stable tin based perovskite solar cells with efficiency over 10% by designing amorphous-polycrystalline nanostructures.

Published
2020
Full Text
View/download PDF

80. Liste des collaborateurs

Author

Brouard, Jacques, primary, Lezmi, Guillaume, additional, Pouessel, Guillaume, additional, Abecassis, Anna, additional, Adel-Patient, Karine, additional, Amat, Flore, additional, Maesano, Isabella Annesi, additional, Barbaud, Annick, additional, Beaudouin, Étienne, additional, Beaumont, Pascale, additional, Bellon, Nathalia, additional, Benoist, Grégoire, additional, Bidat, Étienne, additional, Blanc, Sibylle, additional, Bodemer, Christine, additional, Bonneton, Marjorie, additional, Bradatan, Elena, additional, Branellec, Albanne, additional, Brouard, Jacques, additional, Capelli, Émilie, additional, Carpentier, Olivier, additional, Couderc, Laure, additional, Cros, Pierrick, additional, Dalphin, Marie-Laure, additional, Degraix, Jean-Louis, additional, Delebarre-Sauvage, Christine, additional, Deschildre, Antoine, additional, Divaret-Chauveau, Amandine, additional, Doc, Angélique, additional, Dutau, Guy, additional, Faucon, Caroline, additional, Fauquert, Jean-Luc, additional, Fina, Agnès, additional, Gaitan, Lea, additional, Ganga-Zandzou, Patrice-Serge, additional, Giovannini-Chami, Lisa, additional, Guénard-Bilbault, Lydie, additional, Guiddir, Tamazoust, additional, Hazebrouck, Stéphane, additional, Tanno, Luciana Kase, additional, Ladaurade, Alice, additional, Lageix, Florence, additional, Lavaud, François, additional, Lefèvre, Sébastien, additional, Lejeune, Stéphanie, additional, Pabic, Françoise Le, additional, Metz-Favre, Carine, additional, Michel, Moïse, additional, Moraly, Tomas, additional, Morel-Codreanu, Françoise, additional, Nemni, Ariane, additional, Thi, Nhân Pham, additional, Polivka, Laura, additional, Ponvert, Claude, additional, Rame, Jean-Marc, additional, Renaudin, Jean-Marie, additional, Sabouraud-Leclerc, Dominique, additional, Santos, Adjokè Clarisse, additional, Serrano, Eva, additional, Thumerelle, Caroline, additional, Vitte, Joana, additional, Wanin, Stéphanie, additional, and Zannotti, Mathieu, additional

Published
2021
Full Text
View/download PDF

82. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author

Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology

Subjects
Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion

Published
2021

84. Controversies in drug allergy: Testing for delayed reactions

Author

Phillips, Elizabeth J., Bigliardi, Paul, Bircher, Andreas J., Broyles, Ana, Chang, Yoon-Seok, Chung, Wen-Hung, Lehloenya, Rannakoe, Mockenhaupt, Maja, Peter, Jonny, Pirmohamed, Munir, Roujeau, Jean-Claude, Shear, Neil H., Tanno, Luciana Kase, Trubiano, Jason, Valluzzi, Rocco, and Barbaud, Annick

Published
2019
Full Text
View/download PDF

87. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus

Author

Chasset, François, primary, Jaume, Léa, additional, Mathian, Alexis, additional, Abisror, Noémie, additional, Dutheil, Amélie, additional, Barbaud, Annick, additional, Kottler, Diane, additional, Girard, Céline, additional, Jousse-Joulin, Sandrine, additional, Tauber, Marie, additional, Livideanu, Cristina Bulai, additional, Avettand-Fenoel, Véronique, additional, Lhote, Raphael, additional, Pha, Micheline, additional, and Amoura, Zahir, additional

Published
2023
Full Text
View/download PDF

88. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial – the PRADA trial

Author

Catherine Droitcourt, Sébastien Barbarot, Annabel Maruani, Laure Darrieux, Laurent Misery, Emilie Brenaut, Henri Adamski, Cécile Chabbert, Annie Vermersch, Marie Weiborn, Julien Seneschal, Alain Taïeb, Patrice Plantin, Hervé Maillard, Alice Phan, François Skowron, Manuelle Viguier, Delphine Staumont-Salle, Audrey Nosbaum, Angèle Soria, Annick Barbaud, Emmanuel Oger, Alain Dupuy, and Groupe de Recherche sur l’Eczéma Atopique de la Société Française de Dermatologie (GREAT)

Subjects
Atopic dermatitis, vitamin D, phototherapy, long-term control, add-on therapy, pragmatic trial, Medicine (General), R5-920
Abstract

Abstract Background Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates. Methods This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter. Discussion This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. Trial registration ClinicalTrials.gov Identifier: NCT02537509, first received: 1 September 2015.

Published
2019
Full Text
View/download PDF

89. Dermatite à anthrènes

Author

E. Turquier, P. Senet, P. Moguelet, A. Barbaud, and F. Chasset

Subjects
Ocean Engineering, Safety, Risk, Reliability and Quality
Published
2023

90. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

Author

Jutel M., Torres M.J., Palomares O., Akdis C.A., Eiwegger T., Untersmayr E., Barber D., Zemelka-Wiacek M., Kosowska A., Palmer E., Vieths S., Mahler V., Canonica W.G., Nadeau K., Shamji M.H., Agache I., Akdis M., Khaitov M., Alvarez-Perea A., Alvaro-Lozano M., Atanaskovic-Markovic M., Backer V., Barbaud A., Bavbek S., de Blay F., Bonini M., Bonini S., van Boven J.F.M., Brockow K., Cazzola M., Chatzipetrou A., Chivato T., Cianferoni A., Corren J., Cristoph-Caubet J., Dunn-Galvin A., Ebisawa M., Firinu D., Gawlik R., Gelincik A., del Giacco S., Mortz C.G., Jurgen Hoffmann H., Hoffmann-Sommergruber K., Klimek L., Knol E., Lauerma A., de Llano L.P., Matucci A., Meyer R., Moreira A., Morita H., Patil S.U., Pfaar O., Popescu F.-D., del Pozo V., Price O.J., van Ree R., Fernandez-Rivas M., Rogala B., Romano A., Santos A., Sediva A., Skypala I., Smolinska S., Sokolowska M., Sturm G., Vultaggio A., Walusiak-Skorupa J., Worm M., University of Zurich, Shamji, Mohamed H, Agache, Ioana, Ear, Nose and Throat, Experimental Immunology, AII - Inflammatory diseases, APH - Global Health, APH - Personalized Medicine, Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Subjects
DOWN-REGULATION, COVID-19 Vaccines, Immunology, 610 Medicine & health, IMMUNOGENICITY, 10183 Swiss Institute of Allergy and Asthma Research, VACCINES, INFECTION, Hypersensitivity, Humans, Immunology and Allergy, SARS, 2403 Immunology, Biological Products, T-CELL RESPONSES, SARS-CoV-2, IMMUNE-RESPONSES, Vaccination, AIT, Allergens, Immunoglobulin E, allergy, Asthma, mRNA vaccines, biologicals, Desensitization, Immunologic, SAFETY, 2723 Immunology and Allergy, immunotherapy, INFLUENZA VACCINATION, Covid-19, SEVERE ASTHMA, allergen
Abstract

Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.

Published
2022

93. Intérêt d’une batterie spécialisée de tests épicutanés dans une cohorte de patients adressés pour hypersensibilité à leur implant orthopédique. Une étude multicentrique du DAG

Author

Gautier, C., Giordano-Labadie, F., Marcant, P., Castelain, F., Raison-Peyron, N., Milpied, B., Kurihara, F., Bara, C., Ferrier-Le Bouedec, M.C., Pasteur, J., Tetart, F., Assier, H., Morice, C., Bernier, C., Delaunay, J., Valois, A., Boulard, C., Crepy, M.N., Leleu, C., Chasset, F., Hardy, A., and Barbaud, A.

Published
2024
Full Text
View/download PDF

95. Allergic contact dermatitis from essential oil in consumer products: Mode of uses and value of patch tests with an essential oil series. Results of a French study of the DAG (Dermato‐Allergology group of the French Society of Dermatology).

Author

Barbaud, Annick, Kurihara, Flore, Raison‐Peyron, Nadia, Milpied, Brigitte, Valois, Aude, Assier, Haudrey, Morice, Cécile, Manciet, Jean Romain, Gener, Gwendeline, Giordano‐Labadie, Françoise, Marcant, Pierre, Bernier, Claire, Amsler, Emmanuelle, Crepy, Marie Noelle, Tetart, Florence, Soria, Angèle, and le Bouëdec, Marie‐Christine Ferrier

Subjects
ESSENTIAL oils, TEA tree oil, CONSUMER goods, CONTACT dermatitis, ECZEMA
Abstract

Objective: To analyse the clinical characteristics and sensitivity of an essential oil patch test series (EOS) in patients sensitized to their own essential oils (EOs). Method: We analysed the clinical data and patch test results obtained with the European baseline series (BSE) and an EOS, as well as the mode of use of EOs, through a questionnaire included in the patient file. Results: The study included 42 patients (79% women, average age 50 years) with allergic contact dermatitis (ACD), 8 patients required hospitalization. All patients were sensitized to the EO they used, primarily lavender (Lavandula augustifolia, 8000‐28‐0), tea tree (Melaleuca alternifolia leaf oil, 68647‐73‐4), ravintsara (Cinnamomum camphora oil, 92201‐50‐8), and 2 cases were attributed to helichrysum (helichrysum italicum flower absolute, 90045‐56‐0). 71% had positive patch tests to fragrance mix I or II, 9 only to the EOS and 4 only with their personal EO. Interestingly, 40% of patients did not spontaneously mention the use of EOs, and only 33% received advice on their use at the time of purchase. Conclusion: Patch tests with the BSE, limonene and linalool HP, and oxidized tea tree oil is sufficient to detect most EO‐sensitized patients. The most important is to test the patient's own used EOs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

98. Allergic contact dermatitis caused by PEG‐22 and PEG‐45 dodecyl glycol copolymers in two skin‐repairing creams.

Author

Brehon, Alice, Soria, Angèle, Barbaud, Annick, and Amsler, Emmanuelle

Subjects
ETHYLENE glycol, CONTACT dermatitis, COPOLYMERS, GLYCOLS, ECZEMA, BENZYL alcohol
Abstract

Keywords: allergic contact dermatitis; CAS no. 78336-31-9; case report; copolymers; cosmetic products; PEG-22/dodecyl glycol copolymer; PEG-45/dodecyl glycol copolymer EN allergic contact dermatitis CAS no. 78336-31-9 case report copolymers cosmetic products PEG-22/dodecyl glycol copolymer PEG-45/dodecyl glycol copolymer 213 215 3 08/04/23 20230901 NES 230901 We report a case of allergic contact dermatitis (ACD) caused by PEG-22/dodecyl glycol copolymer and PEG-45/dodecyl glycol copolymer contained in two different "skin-repairing" creams. Allergic contact dermatitis, CAS no. 78336-31-9, case report, copolymers, cosmetic products, PEG-22/dodecyl glycol copolymer, PEG-45/dodecyl glycol copolymer Allergic contact dermatitis caused by PEG-22 and PEG-45 dodecyl glycol copolymers in two skin-repairing creams. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results